Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice
Recruitment status was Not yet recruiting
The prevalence of extended spectrum betalactamase (ESBL) producing bacteria found in urine sample cultures has been increasing over the past decades.
The study hypothesis is to assess the clinical and microbiological outcome of pivmecillinam treatment of ESBL producing E. coli and K. Pneumoni, as well as to observe the clinical and microbiological outcome of the same group of bacteria treated with other antiinfectious agents.
Samples are gathered in primary care setting.
Urinary Tract Infections
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||What is the Outcome of Treatment of Urinary Tract Infections Caused by Bacteria Producing Extended Spectrum Betalactamase in a Primary Care Setting?|
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||February 2013|
|Estimated Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
ESBL producing bacteria
Group of patients with identified ESBL producing bacteria in a urine sample taken in a primary care setting.
Non-ESBL urinary tract infection
Urinary tract infection found in sample taken in a primary care setting where ESBL producing bacteria are not found.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01531023
|Contact: Marianne Bollestad, Mdfirstname.lastname@example.org|
|Study Director:||Morten Lindbaek, Md PhD||University of Oslo|